心肌梗塞治疗药物市场规模、份额、成长分析，按治疗类型、药物类别、给药途径、最终用户、地区 - 产业预测，2025-2032

2023年全球心肌梗塞（MI）治疗市场规模估值为217.5亿美元，从2024年的227.3亿美元增长到2032年的323.2亿美元，在预测期内（2025年）预计复合年增长率为2032 年为4.5%）。

心肌梗塞（MI）治疗市场预计将显着成长，这主要是由于冠状动脉疾病（心臟病发作的主要原因）盛行率不断上升。每年约有 1730 万人死于心臟病，因此寻找有效治疗方案的迫切性从未如此迫切。人口老化、肥胖率上升以及糖尿病和高血压等慢性疾病等因素导致了这一增长。此外，不良饮食习惯和滥用药物等生活方式选择也会增加心肌梗塞的风险。此外，技术进步带来了精确闭塞检测和个人化治疗方法的创新方法，也正在推动市场发展。随着有效治疗方法的推广，心肌梗塞治疗市场预计将扩大，为相关人员创造利润丰厚的机会。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术分析
• 监管分析
• 专利分析
• 案例研究

全球心肌梗塞（MI）治疗市场规模及依治疗类型分類的复合年增长率（2025-2032）

• 市场概况
• 溶栓
  • 链球菌激酶
  • 重组组织胞浆素原原激活剂 (rtPA)
• 经皮皮冠状动脉介入治疗（PCI）
  • 球囊血管成形术
  • 支架置入术（药物释放型支架裸金属支架）
• 冠状动脉绕道手术手术（CABG）
• 药物（手术或介入治疗之前或之后使用）
• 其他新治疗方法

全球心肌梗塞（MI）治疗市场规模及依药物类别分類的复合年增长率（2025-2032）

• 市场概况
• 抗血小板药
• 抗凝血物
• β受体阻断剂
• 他汀类药物（降胆固醇药物）
• Atorvastatin
• 其他的

全球心肌梗塞 (MI) 治疗市场规模及依给药途径分類的复合年增长率 (2025-2032)

• 市场概况
• 口服
• 锭剂
• 胶囊
• 注射
• 静脉注射 (IV)
• 皮下注射（SC）
• 经皮的
• 修补

全球心肌梗塞 (MI) 治疗市场规模及最终用户复合年增长率（2025-2032）

• 市场概况
• 医院
• 专科诊所
• 日间手术中心 (ASC)
• 居家医疗

全球心肌梗塞（MI）治疗市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
• 产品系列分析
• 按细分市场分類的份额分析
• 收益与前一年同期比较（2022-2024）

  主要企业简介

  • 阿斯特捷利康公司（英国）
  • 勃林格殷格翰国际有限公司（德国）
  • 礼来公司（美国）
  • 安进（美国）
  • 诺华公司（瑞士）
  • Idorsia 製药有限公司（瑞士）
  • 法拉第製药（美国）
  • 立即治疗（美国）
  • 三菱化学集团（日本）
  • 坎塞拉（瑞典）
  • 拜耳公司（德国）
  • 雷卡迪奥（美国）
  • Mesoblast 有限公司（澳洲）
  • Athera BIOTechnologies AB（瑞典）
  • 百时美施贵宝公司（美国）
  • CeleCor Therapeutics（美国）
  • CHIESI Farmaceutici SpA（义大利）
  • CSL 有限公司（澳洲）
  • 永至生技（台湾）

结论和建议

Global Myocardial Infarction (MI) Therapeutics Market size was valued at USD 21.75 billion in 2023 and is poised to grow from USD 22.73 billion in 2024 to USD 32.32 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The Myocardial Infarction (MI) Therapeutics Market is poised for significant growth, primarily driven by the rising incidence of coronary artery disease, the leading cause of heart attacks. With approximately 17.3 million global fatalities attributed to heart disease annually, the urgency for effective treatment options has never been higher. Factors such as an aging population, increasing rates of obesity, and chronic conditions like diabetes and hypertension are contributing to this uptick. Additionally, lifestyle choices, including poor diet and substance abuse, are escalating myocardial infarction risk. The market is further bolstered by advancements in technology, promising innovative methods for precise blockage detection and personalized treatment approaches. As effective therapies gain traction, the MI treatment market is expected to expand, presenting lucrative opportunities for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Myocardial Infarction (MI) Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Myocardial Infarction (MI) Therapeutics Market Segmental Analysis

Global Myocardial Infarction (MI) Therapeutics Market is segmented by Therapy Type, Drug Class, Route of Administration, End-User and region. Based on Therapy Type, the market is segmented into Thrombolysis, Primary Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG), Medications (used before or after surgery or intervention therapy) and Other Emerging Therapies. Based on Drug Class, the market is segmented into Antiplatelet Agents, Anticoagulants, Beta-Blockers, Statins (Cholesterol-Lowering Drugs), Atorvastatin and Others. Based on Route of Administration, the market is segmented into Oral, Tablets, Capsules, Injectable, Intravenous (IV), Subcutaneous (SC), Transdermal and Patches. Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCs) and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Myocardial Infarction (MI) Therapeutics Market

The global Myocardial Infarction (MI) Therapeutics Market is expected to experience significant growth due to the increasing prevalence of heart attacks worldwide. Key factors contributing to this growth include the rising rates of coronary artery disease and lifestyle changes, which are leading to more cases of MI. Over the upcoming years, a surge in hypertension, obesity, and smoking prevalence is likely to further stimulate demand for myocardial infarction therapies. As healthcare systems adapt to address these challenges, the market is anticipated to expand, reflecting the growing need for effective treatments and interventions to manage this critical health issue.

Restraints in the Global Myocardial Infarction (MI) Therapeutics Market

The global Myocardial Infarction (MI) Therapeutics Market faces several significant constraints that may impede its growth in the coming years. Chief among these are the escalating costs associated with research and development, alongside limitations in R&D activities. Additionally, rising overall healthcare expenditures, stringent regulatory requirements, and the substantial financial investments needed for clinical trials further compound these challenges. These factors collectively create a challenging environment for companies aiming to innovate and develop effective treatments for myocardial infarction, potentially stunting market expansion and advancements in therapeutic options for patients.

Market Trends of the Global Myocardial Infarction (MI) Therapeutics Market

The Global Myocardial Infarction (MI) Therapeutics Market is increasingly influenced by the integration of nanoparticle technology, facilitating targeted drug delivery and advanced imaging techniques for cardiovascular diseases. Recent innovations in nanoparticle design and functionality are enhancing preclinical research, enabling efficient therapeutic mechanisms that address critical challenges such as low bioavailability and bioimaging inefficiencies. By focusing on specific actions against inflammation, fibrogenesis, and promoting angiogenesis, the development of nanocarrier systems is poised to revolutionize MI treatment. This trend reflects a significant shift toward precision medicine, presenting opportunities for more effective solutions in MI diagnostics and therapeutics, thus shaping the future landscape of cardiovascular care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Myocardial Infarction (MI) Therapeutics Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Thrombolysis
  • Streptokinase
  • Recombinant Tissue Plasminogen Activator (rtPA)
• Primary Percutaneous Coronary Intervention (PCI)
  • Balloon Angioplasty
  • Stenting (Drug-Eluting Stents, Bare-Metal Stents)
• Coronary Artery Bypass Grafting (CABG)
• Medications (used before or after surgery or intervention therapy)
• Other Emerging Therapies

Global Myocardial Infarction (MI) Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antiplatelet Agents
• Anticoagulants
• Beta-Blockers
• Statins (Cholesterol-Lowering Drugs)
• Atorvastatin
• Others

Global Myocardial Infarction (MI) Therapeutics Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Tablets
• Capsules
• Injectable
• Intravenous (IV)
• Subcutaneous (SC)
• Transdermal
• Patches

Global Myocardial Infarction (MI) Therapeutics Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Homecare Settings

Global Myocardial Infarction (MI) Therapeutics Market Size & CAGR (2025-2032)

• North America (Therapy Type, Drug Class, Route of Administration, End-User)
  • US
  • Canada
• Europe (Therapy Type, Drug Class, Route of Administration, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Drug Class, Route of Administration, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Drug Class, Route of Administration, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Drug Class, Route of Administration, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AstraZeneca Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Idorsia Pharmaceuticals Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Faraday Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immediate Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Chemical Group (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kancera (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Recardio (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mesoblast Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Athera Biotechnologies AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CeleCor Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CHIESI Farmaceutici SpA (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Ltd. (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ever Supreme Bio Technology (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations